A phase 1/2a study of safety and efficacy of ALY-101 intradermal injectable in patients suffering from Alopecia Areata (AA)
Latest Information Update: 31 Mar 2025
At a glance
- Drugs ALY-101 (Primary)
- Indications Alopecia areata
- Focus Therapeutic Use
- 27 Mar 2025 According to an Alys Pharmaceuticals media release, the first patient has been dosed in its Phase IIa trial of ALY-101 in patients suffering from Alopecia Areata.
- 27 Mar 2025 Status changed from planning to recruiting as per Alys Pharmaceuticals media release.
- 12 Feb 2025 According to an Alys Pharmaceuticals media release, this phase 1/2a study start in early 2025.